Key Takeaways
- Record Q4, but a mix of forces: Revenue grew 38% and EBITDA roughly 90%, driven by the distribution stock-and-sale model and manufacturing volume growth, though part of the EBITDA lift came from inventory gains.
- The Middle East crisis became a net opportunity: The company overrode regional disruption to emerge as a more reliable supplier to key end users, with only a small 15-day impact window and no energy-cost exposure.
- Strategic pivot underway in manufacturing: Exiting the Morbi ceramic binder business and advancing the PAM solid and specialty amines projects signals a deliberate shift toward higher-value acrylamide applications.
- Management refuses to pin a number on FY27: The company declined to endorse any EBITDA or revenue growth figure for FY27, calling such assumptions low-value given the number of moving parts.
- What to watch next quarter: Whether the strong merchant export pipeline converts into reported revenue, the pace of new downstream product commercialization, and any decision on the Koei specialty amines project.
Q4 Performance: The Surge and Its Composition
- Top-line jump: Revenue grew 38% YoY, powered by the stock-and-sale model in distribution plus volume growth in manufacturing, even as full-year standalone revenue dipped slightly on sustained chemical-price deflation through March 2026.
- EBITDA nearly doubled: The roughly 90% EBITDA expansion reflected both operational gains and inventory gains, with management asserting the result is sustainable as far as they can foresee.
- Inventory gain acknowledged, not isolated: Management described Q4 EBITDA as a mix of operational and inventory gain, noting that volumes increased for key products during the year and only a small 15-day period was disrupted by the Middle East war.
- Balance-sheet strength: The company remains debt-free, and inventories reduced as market share expanded and new customers were added, improving the overall material balance.
Ambarish Daga: "In terms of the question on Q4, whether it was operational gain or just inventory gain, so I would say it is a mix of both... it is not just about inventory gain on a one-time basis, it is going to be sustainable as far as we can foresee."
Geopolitics: From Risk to Reliability
- Middle East crisis overridden: The company came out stronger as a reliable supplier to key end users during the regional disruption, with only a small 15-day impact window in Q4.
- No energy-cost exposure: The war's impact on energy cost was limited because the company is not dependent on gas; only some distribution-business products saw a small effect.
- Raw-material price spike managed: Acrylonitrile prices shot up drastically in March with the onset of the war, but the company had good realization throughout the year through sales efforts and proactive procurement.
- US tariff headwind: Merchant exports suffered a shortfall because US tariff policies acted as a deterrent, and offtake from the US oil and gas sector reduced during the year.
Manufacturing: Volume Growth and Strategic Reshaping
- Acrylamide liquid and NMA volumes up significantly: New customer additions in domestic and export markets, plus the exit from the ceramic binder business in Morbi, contributed to increased acrylamide liquid volumes.
- Margin improvement levers: Better raw-material management and operational efficiencies lifted manufacturing margins, while acrylamide powder volumes remained stable despite continual Chinese imports.
- Exit from Morbi ceramic binders: The strategic decision to exit this business aligns with a focus on strengthening upstream acrylamide and expanding into higher-value applications.
- R&D engine now running: The new Navi Mumbai laboratory is concentrating on innovations and opportunities from relationships, with new downstream acrylamide products under development.
Project Pipeline: Piloting, Partnerships, and No Dates
- PAM solid project advancing: The project has progressed to piloting, with management hoping to start commercialization activities during the current year.
- Specialty amines with Koei Chemicals: The joint project is progressing as planned, with a decision expected during the current year.
- New downstream acrylamide products: The R&D team is developing these, and management is hopeful they will add to manufacturing offerings in future quarters.
- Capacity utilization ambition: The company hopes to achieve maximum possible utilization for manufactured products in both FY27 and FY28.
Outlook: Subdued Near-Term, Pipeline-Led Recovery
- Chemical distribution: Near-term Q1 demand is likely to remain subdued due to global uncertainties, but higher pricing overall should drive revenue upwards during the quarter.
- Merchant exports: A strong order pipeline is seen, which should turn into healthy performance during Q1.
- Acrylamide export demand picking up: Export demand has started to recover in the second half of the current quarter, supported by REACH registration, KKDIK pre-registration, and international exhibition participation.
- NMA as a growth driver: Volumes are expected to remain stable, with new customer addition the primary growth lever.
- Top-line target: Management is targeting an increase in overall top line from the previous year at current market prices, depending on market conditions and penetration.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Top-line growth | Increase overall top line from previous year at current market prices, subject to market conditions and penetration | FY27 |
| Capacity utilization | Achieve maximum possible utilization for manufactured products | FY27 and FY28 |
| PAM solid commercialization | Advance from piloting to commercialization activities | During the current year |
| Specialty amines decision | Take a decision on the Koei Chemicals joint project | During the current year |
| Merchant export recovery | Strong order pipeline to convert into healthy performance | Q1 FY27 |
| New downstream acrylamide products | Add to manufacturing offerings | Future quarters (undated) |
Ambarish Daga: "It is difficult to put down any number as an assumption because it will not hold much value. There are too many different factors that go into a number. So, I would rather you stay away from giving you any number."
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue growth | 38% YoY |
| EBITDA growth | ~90% YoY |
| EBITDA margin | 11%, up from 9.7% YoY |
| Earnings per share | Improved YoY |
| Dividend | 125% recommended for FY26 |
| Manufacturing revenue share | ~35% of total revenue (FY26 full year), balance from distribution |
| Acrylamide liquid capacity | 32,000 MTPA, of which 20,000 MTPA for merchant sales |
| Acrylamide solid capacity | 3,600 MTPA |
| N-methylol acrylamide (NMA) capacity | 2,000 MTPA |
| Q4 EBITDA run-rate | ₹13 cr per quarter (per an analyst's math) |
| FY27 EBITDA target | ₹50 cr (per an analyst's math) |